Jiangsu Sihuan Bioengineering Co Ltd

Jiangsu Sihuan Bioengineering Co Ltd (000518.SZ) is currently classified as Pharmaceuticals & Medical Research within Pharmaceuticals (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 648,501,210 CNY, total equity 470,648,860, short-term debt 0, long-term debt 47,674,750. Net cash position is approximately -47,674,750 CNY. Self-calculated market cap is 4,416,796,192 CNY (market_price × shares_outstanding_diluted). Profitability profile: revenue 49,409,530, gross profit 29,794,190, operating income -6,324,230, net income -8,090,880. Return on equity ~-1.7%. Return on assets ~-1.2%. Operating-cash-flow to net-income ratio is 0.01. Risk profile from automated assessment: liquidity risk medium, dilution risk low. Flags: Net cash is negative after subtracting total debt..

Jiangsu Sihuan Bioengineering Co Ltd (000518.SZ) has been formally classified within the Healthcare economic sector, specifically under the Pharmaceuticals & Medical Research activity. This taxonomic update provides a clearer definition of the company’s operational focus, aligning its market identity with its core business functions in the medical research and pharmaceutical space. Alongside this classification, the company’s risk profile has been updated with new assessments. Dilution risk is now categorized as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment offers investors a baseline understanding of the equity stability associated with the firm. Conversely, liquidity risk has been assessed at a medium level. This designation suggests that while the company maintains operational viability, there may be moderate constraints or variability in its ability to meet short-term financial obligations or trade volumes compared to peers with lower liquidity risk profiles. These updates collectively refine the analytical framework for Jiangsu Sihuan Bioengineering, moving from an undefined state to a structured profile with specific sector and risk attributes. The combination of a low dilution risk and medium liquidity risk, set against a clear pharmaceutical sector classification, provides a more nuanced foundation for evaluating the company’s financial health and market positioning.

Revenue surged 69.2% year-over-year in 2009, reaching 344.4 million CNY, signaling a strong operational turnaround.

Net income improved by 66.3% year-over-year in 2009, narrowing the loss to 37.1 million CNY.

Free cash flow improved by 71.6% year-over-year in 2009, reducing the outflow to 28.9 million CNY.

The company maintains a low debt-to-equity ratio of 0.1, indicating conservative leverage compared to peers.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value.

Cash conversion ratio of 0.01 is in the bottom quartile, indicating poor efficiency in generating cash from earnings.

Liquidity risk is rated as medium, posing potential challenges for meeting short-term financial obligations.

Revenue ¥81.2M, +85,1% YoY; Operating income +14,0% YoY.

• ▍Revenue ¥81.2M, +85,1% YoY
• ▍Operating income +14,0% YoY
• ▍Net income +28,9% YoY
• ▍Net margin -13.9%

Revenue ¥50.0M, +5,2% YoY; Operating income +56,7% YoY.

• ▍Revenue ¥50.0M, +5,2% YoY
• ▍Operating income +56,7% YoY
• ▍Net income +74,4% YoY
• ▍Net margin -48.8%

Revenue ¥112.5M, +124,1% YoY; Operating income +53,5% YoY.

• ▍Revenue ¥112.5M, +124,1% YoY
• ▍Operating income +53,5% YoY
• ▍Net income +27,0% YoY
• ▍Net margin -2.3%

Revenue ¥138.1M, +179,4% YoY; Operating income +160,7% YoY.

• ▍Revenue ¥138.1M, +179,4% YoY
• ▍Operating income +160,7% YoY
• ▍Net income +171,9% YoY
• ▍Net margin 4.2%

Revenue ¥43.8M; Operating income -¥14.5M.

• ▍Revenue ¥43.8M
• ▍Operating income -¥14.5M
• ▍Net margin -36.3%

Revenue ¥47.5M; Operating income -¥63.3M.

• ▍Revenue ¥47.5M
• ▍Operating income -¥63.3M
• ▍Net margin -200.7%

Revenue ¥49.4M; Operating income -¥6.3M.

• ▍Revenue ¥49.4M
• ▍Operating income -¥6.3M
• ▍Net margin -16.4%

Revenue ¥50.2M; Operating income -¥5.2M.

• ▍Revenue ¥50.2M
• ▍Operating income -¥5.2M
• ▍Net margin -7.1%

Revenue ¥344.4M, +69,2% YoY; Operating income +47,9% YoY.

• ▍Revenue ¥344.4M, +69,2% YoY
• ▍Operating income +47,9% YoY
• ▍Net income +66,3% YoY
• ▍Free cash flow +71,6% YoY
• ▍Net margin -10.8%

Revenue ¥203.5M, −13,6% YoY; Operating income −3,1% YoY.

• ▍Revenue ¥203.5M, −13,6% YoY
• ▍Operating income −3,1% YoY
• ▍Net income −46,1% YoY
• ▍Free cash flow −49,5% YoY
• ▍Net margin -54.0%

Revenue ¥235.4M, −12,9% YoY; Operating income −41,3% YoY.

• ▍Revenue ¥235.4M, −12,9% YoY
• ▍Operating income −41,3% YoY
• ▍Net income −54,3% YoY
• ▍Free cash flow −66,3% YoY
• ▍Net margin -32.0%

Revenue ¥270.1M, −23,0% YoY; Operating income −52,1% YoY.

• ▍Revenue ¥270.1M, −23,0% YoY
• ▍Operating income −52,1% YoY
• ▍Net income −40,2% YoY
• ▍Free cash flow −65,5% YoY
• ▍Net margin -18.1%